Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Metabolic disorders
Biotech
Relmada reconsiders plans to test psilocybin for obesity
Relmada’s attempts to see whether a magic mushroom extract could be used to treat obesity may be coming to an end before they really began.
James Waldron
Mar 28, 2025 10:00am
Novo bets up to $354M per target on Gensaic’s delivery tech
Mar 3, 2025 8:37am
Lilly inks $50M deal for biotech's FXR program
Feb 26, 2025 5:35am
Novo inks $50M metabolic disease pact with genomics biotech
Jan 7, 2025 10:35am
Advantage spins out anti-aging R&D to new biotech Klothea
Nov 25, 2024 11:56am
UPDATE: Lilly-backed metabolic disease biotech files IPO
Sep 4, 2024 10:23am
